Breaking News

Today
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Hot Stocks
Moderna says over 26,500 participants received second shot in study » 09:53
10/22/20
10/22
09:53
10/22/20
09:53
MRNA

Moderna

$69.84 /

+1.47 (+2.15%)

Moderna said that to…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
MRNA Moderna
$69.84 /

+1.47 (+2.15%)

MRNA Moderna
$69.84 /

+1.47 (+2.15%)

10/08/20 Piper Sandler
Moderna regains rights to adult RSV vaccine mRNA-1172, Piper ups target to $136
10/06/20 Raymond James
Raymond James says FDA guidance 'likely assures' no vaccine EUA before late Nov.
09/18/20 Needham
Moderna shares attractive long term on mRNA platform and pipeline, says Needham
09/17/20 Jefferies
Moderna COVID trial stats suggest late Oct. or Nov. for data, says Jefferies
MRNA Moderna
$69.84 /

+1.47 (+2.15%)

  • 19
    May
  • 12
    Feb
MRNA Moderna
$69.84 /

+1.47 (+2.15%)

MRNA Moderna
$69.84 /

+1.47 (+2.15%)

MRNA Moderna
$69.84 /

+1.47 (+2.15%)

Hot Stocks
Moderna says partner PPD 'essential' in Phase 3 Covid study » 09:51
10/22/20
10/22
09:51
10/22/20
09:51
MRNA

Moderna

$69.23 /

+0.86 (+1.26%)

, PPD

PPD, Inc.

$36.15 /

+ (+0.00%)

Moderna (MRNA) said its…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
MRNA Moderna
$69.23 /

+0.86 (+1.26%)

PPD PPD, Inc.
$36.15 /

+ (+0.00%)

MRNA Moderna
$69.23 /

+0.86 (+1.26%)

10/08/20 Piper Sandler
Moderna regains rights to adult RSV vaccine mRNA-1172, Piper ups target to $136
10/06/20 Raymond James
Raymond James says FDA guidance 'likely assures' no vaccine EUA before late Nov.
09/18/20 Needham
Moderna shares attractive long term on mRNA platform and pipeline, says Needham
09/17/20 Jefferies
Moderna COVID trial stats suggest late Oct. or Nov. for data, says Jefferies
PPD PPD, Inc.
$36.15 /

+ (+0.00%)

10/12/20 Truist
PPD, Inc. initiated with a Buy at Truist
09/22/20 Mizuho
PPD, Inc. price target raised to $38 from $35 at Mizuho
09/21/20 Baird
PPD, Inc. price target raised to $40 from $36 at Baird
08/06/20 Mizuho
PPD, Inc. price target raised to $35 from $29 at Mizuho
MRNA Moderna
$69.23 /

+0.86 (+1.26%)

PPD PPD, Inc.
$36.15 /

+ (+0.00%)

  • 17
    Sep
  • 19
    May
  • 12
    Feb
  • 06
    Feb
MRNA Moderna
$69.23 /

+0.86 (+1.26%)

MRNA Moderna
$69.23 /

+0.86 (+1.26%)

PPD PPD, Inc.
$36.15 /

+ (+0.00%)

MRNA Moderna
$69.23 /

+0.86 (+1.26%)

Hot Stocks
Moderna completes enrollment in 30,000 person Phase 3 Covid study » 09:48
10/22/20
10/22
09:48
10/22/20
09:48
MRNA

Moderna

$68.74 /

+0.37 (+0.54%)

Moderna announced that it…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
MRNA Moderna
$68.74 /

+0.37 (+0.54%)

MRNA Moderna
$68.74 /

+0.37 (+0.54%)

10/08/20 Piper Sandler
Moderna regains rights to adult RSV vaccine mRNA-1172, Piper ups target to $136
10/06/20 Raymond James
Raymond James says FDA guidance 'likely assures' no vaccine EUA before late Nov.
09/18/20 Needham
Moderna shares attractive long term on mRNA platform and pipeline, says Needham
09/17/20 Jefferies
Moderna COVID trial stats suggest late Oct. or Nov. for data, says Jefferies
MRNA Moderna
$68.74 /

+0.37 (+0.54%)

  • 19
    May
  • 12
    Feb
MRNA Moderna
$68.74 /

+0.37 (+0.54%)

MRNA Moderna
$68.74 /

+0.37 (+0.54%)

MRNA Moderna
$68.74 /

+0.37 (+0.54%)

Yesterday
Periodicals
Eli Lilly hires advisor to review plant producing C-19 treatment, CNBC reports » 08:26
10/21/20
10/21
08:26
10/21/20
08:26
LLY

Eli Lilly

$143.57 /

+0.93 (+0.65%)

Eli Lilly has hired an…

Eli Lilly has hired an outside advisor to review a plant that had been cited for a variety of issues by the Food and Drug Administration, CNBC reports. The plant had been producing the drugmaker's experimental Covid-19 treatment. The company has not received a warning letter from the FDA following inspections at the plant which were first reported by Reuters last week and had received an Official Action Indicated notice from the FDA in relation to issues at the plant. Reference Link

ShowHide Related Items >><<
LLY Eli Lilly
$143.57 /

+0.93 (+0.65%)

LLY Eli Lilly
$143.57 /

+0.93 (+0.65%)

10/16/20 JPMorgan
Eli Lilly price target raised to $200 from $190 at JPMorgan
10/14/20 JPMorgan
Eli Lilly risk/reward favorable into tirzepatide readout, says JPMorgan
10/14/20 Citi
Karuna Therapeutics trial news a positive, says Citi
10/08/20 Benchmark
Regeneron antibody data 'more convincing' than Eli Lilly's, says Benchmark
LLY Eli Lilly
$143.57 /

+0.93 (+0.65%)

LLY Eli Lilly
$143.57 /

+0.93 (+0.65%)

LLY Eli Lilly
$143.57 /

+0.93 (+0.65%)

LLY Eli Lilly
$143.57 /

+0.93 (+0.65%)

Tuesday
Periodicals
Moderna sees Covid-19 interim vaccine results in November, WSJ reports » 06:32
10/20/20
10/20
06:32
10/20/20
06:32
MRNA

Moderna

$70.95 /

-3.005 (-4.06%)

, PFE

Pfizer

$37.81 /

-0.15 (-0.40%)

Moderna (MRNA) CEO…

Moderna (MRNA) CEO Stephane Bancel says the federal government could authorize emergency use of the company's experimental Covid-19 vaccine in December if the company gets positive interim results in November from a large clinical trial, The Wall Street Journal's Peter Loftus reports, citing comments made during the publication's annual Tech Live conference. However, the CEO cautioned that if sufficient interim results from the study takes longer to get, government authorization of the vaccine may not occur until early next year. Pfizer (PFE) said last week it expects to seek U.S. authorization of emergency use of its vaccine by late November. Reference Link

ShowHide Related Items >><<
PFE Pfizer
$37.81 /

-0.15 (-0.40%)

MRNA Moderna
$70.95 /

-3.005 (-4.06%)

MRNA Moderna
$70.95 /

-3.005 (-4.06%)

10/08/20 Piper Sandler
Moderna regains rights to adult RSV vaccine mRNA-1172, Piper ups target to $136
10/06/20 Raymond James
Raymond James says FDA guidance 'likely assures' no vaccine EUA before late Nov.
09/18/20 Needham
Moderna shares attractive long term on mRNA platform and pipeline, says Needham
09/17/20 Jefferies
Moderna COVID trial stats suggest late Oct. or Nov. for data, says Jefferies
PFE Pfizer
$37.81 /

-0.15 (-0.40%)

10/14/20 SVB Leerink
BioNTech price target raised to $69 from $62 at SVB Leerink
10/12/20
Fly Intel: Top five analyst downgrades
10/12/20 Atlantic Equities
Pfizer downgraded to Neutral from Overweight at Atlantic Equities
10/12/20 Atlantic Equities
Pfizer downgraded to Neutral from Overweight at Atlantic Equities
PFE Pfizer
$37.81 /

-0.15 (-0.40%)

MRNA Moderna
$70.95 /

-3.005 (-4.06%)

  • 19
    May
  • 12
    Feb
PFE Pfizer
$37.81 /

-0.15 (-0.40%)

MRNA Moderna
$70.95 /

-3.005 (-4.06%)

PFE Pfizer
$37.81 /

-0.15 (-0.40%)

MRNA Moderna
$70.95 /

-3.005 (-4.06%)

PFE Pfizer
$37.81 /

-0.15 (-0.40%)

MRNA Moderna
$70.95 /

-3.005 (-4.06%)

Friday
Recommendations
Eli Lilly price target raised to $200 from $190 at JPMorgan » 08:49
10/16/20
10/16
08:49
10/16/20
08:49
LLY

Eli Lilly

$146.76 /

-1.59 (-1.07%)

JPMorgan analyst Chris…

JPMorgan analyst Chris Schott raised the firm's price target on Eli Lilly to $200 from $190 and keeps an Overweight rating on the shares. The analyst remains constructive on U.S. Major Pharma sector heading into Q3 earnings reports. Most franchises are showing continued recovery for their COVID-19 impacted franchises and currency should represent a tailwind with a lower U.S. dollar, Schott tells investors in a research note. The stocks have underperformed year-to-date despite an "attractive" new product cycle, continued pipeline momentum, and multiple product catalysts ahead, says the analyst.

ShowHide Related Items >><<
LLY Eli Lilly
$146.76 /

-1.59 (-1.07%)

LLY Eli Lilly
$146.76 /

-1.59 (-1.07%)

10/14/20 JPMorgan
Eli Lilly risk/reward favorable into tirzepatide readout, says JPMorgan
10/14/20 Citi
Karuna Therapeutics trial news a positive, says Citi
10/08/20 Benchmark
Regeneron antibody data 'more convincing' than Eli Lilly's, says Benchmark
10/07/20 Goldman Sachs
Goldman says Lilly comments support need for multiple COVID-19 antibody makers
LLY Eli Lilly
$146.76 /

-1.59 (-1.07%)

LLY Eli Lilly
$146.76 /

-1.59 (-1.07%)

LLY Eli Lilly
$146.76 /

-1.59 (-1.07%)

LLY Eli Lilly
$146.76 /

-1.59 (-1.07%)

Over a week ago
Hot Stocks
Eli Lilly to acquire Disarm Therapeutics for upfront payment of $135M » 09:21
10/15/20
10/15
09:21
10/15/20
09:21
LLY

Eli Lilly

$148.39 /

-1.68 (-1.12%)

Eli Lilly and Company…

Eli Lilly and Company announced a definitive agreement to acquire Disarm Therapeutics, a privately-held biotechnology company creating a new class of disease-modifying therapeutics for patients with axonal degeneration. Disarm has discovered novel, potent SARM1 inhibitors and is advancing them in preclinical development, with the goal of delivering breakthrough treatments to patients with peripheral neuropathy and other neurological diseases such as amyotrophic lateral sclerosis and multiple sclerosis. Under the terms of the agreement, Lilly will acquire Disarm for an upfront payment of $135M. Disarm equityholders may be eligible for up to $1.225B in additional future payments for potential development, regulatory and commercial milestones should Lilly successfully develop and commercialize new medicines resulting from the acquisition. This transaction will be reflected in Lilly's reported results and financial guidance according to Generally Accepted Accounting Principles. There will be no change to Lilly's 2020 non-GAAP earnings per share guidance as a result of this transaction.

ShowHide Related Items >><<
LLY Eli Lilly
$148.39 /

-1.68 (-1.12%)

LLY Eli Lilly
$148.39 /

-1.68 (-1.12%)

10/14/20 JPMorgan
Eli Lilly risk/reward favorable into tirzepatide readout, says JPMorgan
10/14/20 Citi
Karuna Therapeutics trial news a positive, says Citi
10/08/20 Benchmark
Regeneron antibody data 'more convincing' than Eli Lilly's, says Benchmark
10/07/20 Goldman Sachs
Goldman says Lilly comments support need for multiple COVID-19 antibody makers
LLY Eli Lilly
$148.39 /

-1.68 (-1.12%)

LLY Eli Lilly
$148.39 /

-1.68 (-1.12%)

LLY Eli Lilly
$148.39 /

-1.68 (-1.12%)

LLY Eli Lilly
$148.39 /

-1.68 (-1.12%)

Hot Stocks
Eli Lilly supports DSMB decision to pause enrollment in ACTIV-3 clinical trial » 09:16
10/14/20
10/14
09:16
10/14/20
09:16
LLY

Eli Lilly

$150.07 /

-4.42 (-2.86%)

Eli Lilly issued a…

Eli Lilly issued a statement on the NIAID decision to pause enrollment in the ACTIV-3 clinical trial, stating in part: "Since the beginning of the COVID-19 pandemic, Lilly has brought the full force of our scientific capabilities to fight this new disease, collaborating with the U.S. government and industry partners to discover potential treatments. Together, we have sought to learn about the potential impact of neutralizing antibodies across the broadest set of patients even as we were still evolving in our understanding of SARS-CoV-2 virus pathology. As always, we have remained deeply committed to patient safety. As of last evening, Lilly continued to be in communication with the trial sponsor regarding the recommendation from the independent data safety monitoring board, DSMB, of the ACTIV-3 clinical trial to pause enrollment of the study. ACTIV-3, which is evaluating Lilly's investigational neutralizing antibody bamlanivimab, LY-CoV555, as a treatment for COVID-19 in hospitalized patients, is sponsored by the National Institute of Allergy and Infectious Diseases, NIAID, part of the National Institutes of Health, NIH. At this time, only the DSMB has reviewed the data from the trial, and NIH leadership and Lilly remain blinded to the ongoing trial results. Lilly trusts the judgment of the independent DSMB and supports its decisions to exercise caution in ensuring the safety of the patients participating in this study. Importantly, the DSMB also considered the impact of the ACTIV-3 study pause on ACTIV-2 and did not recommend any changes to that study's design or enrollment." Reference Link

ShowHide Related Items >><<
LLY Eli Lilly
$150.07 /

-4.42 (-2.86%)

LLY Eli Lilly
$150.07 /

-4.42 (-2.86%)

10/14/20 JPMorgan
Eli Lilly risk/reward favorable into tirzepatide readout, says JPMorgan
10/14/20 Citi
Karuna Therapeutics trial news a positive, says Citi
10/08/20 Benchmark
Regeneron antibody data 'more convincing' than Eli Lilly's, says Benchmark
10/07/20 Goldman Sachs
Goldman says Lilly comments support need for multiple COVID-19 antibody makers
LLY Eli Lilly
$150.07 /

-4.42 (-2.86%)

LLY Eli Lilly
$150.07 /

-4.42 (-2.86%)

LLY Eli Lilly
$150.07 /

-4.42 (-2.86%)

LLY Eli Lilly
$150.07 /

-4.42 (-2.86%)

Recommendations
Eli Lilly risk/reward favorable into tirzepatide readout, says JPMorgan » 08:23
10/14/20
10/14
08:23
10/14/20
08:23
LLY

Eli Lilly

$150.07 /

-4.42 (-2.86%)

JPMorgan analyst Chris…

JPMorgan analyst Chris Schott sees a favorable risk/reward on Eli Lilly shares into the Phase 3 tirzepatide SURPASS-1 data expected in Q4. Tirzepatide is poised to become Lilly's largest product and further extend its GLP-1 franchise with a potential best-in-class product profile if the drug can replicate Phase 2 efficacy results while improving high-dose tolerability, Schott tells investors in a research note Expectations on tirzepatide have come down recently but remain fairly high into this readout, says the analyst. He sees 5%-10% share upside on "clean" Phase 3 safety and efficacy results across all doses.

ShowHide Related Items >><<
LLY Eli Lilly
$150.07 /

-4.42 (-2.86%)

LLY Eli Lilly
$150.07 /

-4.42 (-2.86%)

10/14/20 Citi
Karuna Therapeutics trial news a positive, says Citi
10/08/20 Benchmark
Regeneron antibody data 'more convincing' than Eli Lilly's, says Benchmark
10/07/20 Goldman Sachs
Goldman says Lilly comments support need for multiple COVID-19 antibody makers
10/07/20 Canaccord
Eli Lilly data further validates COVID antibody therapy, says Canaccord
LLY Eli Lilly
$150.07 /

-4.42 (-2.86%)

LLY Eli Lilly
$150.07 /

-4.42 (-2.86%)

LLY Eli Lilly
$150.07 /

-4.42 (-2.86%)

LLY Eli Lilly
$150.07 /

-4.42 (-2.86%)

Hot Stocks
Moderna receives confirmation that mRNA-1273 is eligible for EMA MAA submission » 08:08
10/14/20
10/14
08:08
10/14/20
08:08
MRNA

Moderna

$78.29 /

+2.92 (+3.87%)

Moderna announced that it…

Moderna announced that it has received written confirmation from the European Medicine Agency, or EMA, that mRNA-1273, the company's vaccine candidate against COVID-19, is eligible for submission of an application for a European Union Marketing Authorization under the Agency's centralized procedure. Confirmation of eligibility was given in response to the submission of a letter of intent enabling Moderna to evaluate the opportunity for submitting a Marketing Authorization Application, or MAA, for mRNA-1273 with the EMA. This submission follows positive results from a preclinical viral challenge study and the positive interim analysis of the Phase 1 study of mRNA-1273 in healthy adults and older adults published in the New England Journal of Medicine. In Europe, the company is working with its strategic manufacturing partners, Lonza of Switzerland and ROVI of Spain, for manufacturing and fill-finish outside of the United States. This is a dedicated supply chain to support Europe and countries other than the United States that enter into purchase agreements with Moderna. The Phase 1 interim analysis showed that mRNA-1273 was generally well-tolerated across all age groups and induced rapid and strong immune responses against SARS-CoV-2. In the 18-55 age group, neutralizing antibody titers were observed in 100% of evaluated participants and at the 100 microgram dose level selected for Phase 3, the geometric mean titers were above those seen in convalescent sera. Similarly, mRNA-1273 induced consistently high levels of pseudovirus neutralization antibody titers in all participants in the 56-70 and 71+ age groups. In addition, vaccination with mRNA-1273 elicited Th1-biased CD4 T cell responses in all age groups. MRNA-1273 is currently being studied in a Phase 3 randomized, 1:1 placebo-controlled trial of 30,000 participants at the 100 microgram dose level in the U.S. As of Friday, October 9, the Phase 3 COVE study has enrolled approximately 28,618 participants with more than 22,194 having received their second vaccination.

ShowHide Related Items >><<
MRNA Moderna
$78.29 /

+2.92 (+3.87%)

MRNA Moderna
$78.29 /

+2.92 (+3.87%)

10/08/20 Piper Sandler
Moderna regains rights to adult RSV vaccine mRNA-1172, Piper ups target to $136
10/06/20 Raymond James
Raymond James says FDA guidance 'likely assures' no vaccine EUA before late Nov.
09/18/20 Needham
Moderna shares attractive long term on mRNA platform and pipeline, says Needham
09/17/20 Jefferies
Moderna COVID trial stats suggest late Oct. or Nov. for data, says Jefferies
MRNA Moderna
$78.29 /

+2.92 (+3.87%)

  • 19
    May
  • 12
    Feb
MRNA Moderna
$78.29 /

+2.92 (+3.87%)

MRNA Moderna
$78.29 /

+2.92 (+3.87%)

MRNA Moderna
$78.29 /

+2.92 (+3.87%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.